Advertisement

DiaMedica Therapeutics Inc. DMAC

Set alert

Price alert · DMAC

All alert types
9.25 USD -0.27 -2.84%

At close · Oct 30

9.25 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
9.27 × 2
Ask
9.28 × 2
9.17 Day range 9.54
5.25 52-week range 10.42
YTD
+16.21%
1 year
+32.14%
Open
9.39
Prev close
9.52
Mkt cap
498.81M
Vol
174.65K
Avg vol
185.28K
EPS
-0.72
P/E
0.00
Div yield
0.00%
More statistics
Low
9.17
High
9.54
Forward P/E
-7.26
Beta
1.46
Short ratio
3.88
Inst. own
31.61%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
4.69
200-d avg
3.61
1y target
7.00

1m chart

Chart tools
Interval

Built from the cached one-day intraday bars.

Signals (39)
NameTimeAgo
MACD: Sell SignalOct 30, 2:18 PM2 days ago
SMA: BullishOct 30, 1:56 PM2 days ago
RSI: OverboughtOct 30, 1:56 PM2 days ago
SMA: BullishOct 30, 1:41 PM2 days ago
MACD: Buy SignalOct 30, 1:41 PM2 days ago
MACD: Sell SignalOct 30, 1:33 PM2 days ago
SMA: BearishOct 30, 1:32 PM2 days ago
RSI: OversoldOct 30, 1:32 PM2 days ago
MACD: Buy SignalOct 30, 1:29 PM2 days ago
RSI: OversoldOct 30, 1:19 PM2 days ago
MACD: Sell SignalOct 30, 1:08 PM2 days ago
SMA: BearishOct 30, 1:07 PM2 days ago
SMA: BearishOct 30, 1:07 PM2 days ago
RSI: OverboughtOct 30, 1:02 PM2 days ago
SMA: BullishOct 30, 12:54 PM2 days ago
MACD: Buy SignalOct 30, 12:49 PM2 days ago
MACD: Sell SignalOct 30, 12:33 PM2 days ago
SMA: BearishOct 30, 12:23 PM2 days ago
MACD: Buy SignalOct 30, 12:16 PM2 days ago
RSI: OversoldOct 30, 12:10 PM2 days ago
MACD: Sell SignalOct 30, 12:08 PM2 days ago
MACD: Buy SignalOct 30, 11:52 AM2 days ago
SMA: BearishOct 30, 11:40 AM2 days ago
SMA: BearishOct 30, 11:40 AM2 days ago
RSI: OversoldOct 30, 11:32 AM2 days ago
SMA: BearishOct 30, 11:30 AM2 days ago
MACD: Sell SignalOct 30, 11:30 AM2 days ago
MACD: Buy SignalOct 30, 11:25 AM2 days ago
RSI: OverboughtOct 30, 11:23 AM2 days ago
SMA: BullishOct 30, 11:17 AM2 days ago
SMA: BullishOct 30, 11:17 AM2 days ago
MACD: Sell SignalOct 30, 11:04 AM2 days ago
RSI: OverboughtOct 30, 10:41 AM2 days ago
SMA: BullishOct 30, 10:36 AM2 days ago
MACD: Buy SignalOct 30, 10:32 AM2 days ago
RSI: OversoldOct 30, 10:18 AM2 days ago
SMA: BearishOct 30, 10:08 AM2 days ago
SMA: BullishOct 30, 9:56 AM2 days ago
RSI: OverboughtOct 30, 9:45 AM2 days ago

Key statistics

Market cap
229.84M
Enterprise value
122.45M
Trailing P/E
0.00
Forward P/E
-7.26
PEG ratio
0.00
Price / sales
0.00
Price / book
4.00
EPS (TTM)
-0.56
Beta
1.46
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-11.14M
Total cash
54.05M
Total debt
388.00K
Return on equity
-35.18%
Shares outstanding
42.76M
Short % of float
0.59%
50-day average
4.69
200-day average
3.61

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 7.00 -24.3% downside
Target (low)
6.00
Target (mean)
7.00
Target (high)
8.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 7, 2024

Expected Aug 7, 2024. Consensus EPS estimate -0.1725.

Earnings history

Financials — quick view

All financials
DMAC Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DMAC Net income — quarterly -10.15M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DMAC EPS — quarterly -0.19
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DMAC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.15-0.150.000.00%
Aug 7, 2024Jun 1, 2024-0.16-0.13+0.03+18.75%
Aug 7, 2024Jun 1, 2024-0.16———
May 8, 2024Mar 1, 2024-0.16-0.14+0.02+12.50%
May 8, 2024Mar 1, 2024-0.16———
Mar 19, 2024Dec 1, 2023-0.14-0.140.000.00%

Upgrades / downgrades

DMAC analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Oct 10, 2024HC Wainwright & Co.reitBuyBuy
Oct 7, 2024HC Wainwright & Co.init—Buy
Aug 16, 2024OppenheimerreitOutperformOutperform
Mar 21, 2024Craig-HallummainBuyBuy
Mar 21, 2024OppenheimerreitOutperformOutperform

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DMAC — it syncs with the Stock Master app.

Insider holders

DMAC insider holders
InsiderRelationLatest transactionDateShares held
GIUFFRE RANDALL MICHAELDirectorStock Award(Grant)Jan 1, 2024411,194
KELLEN SCOTTChief Financial OfficerPurchaseJun 22, 202332,290
KUNTZ RICHARD PDirectorStock Award(Grant)Jan 1, 202414,285
PARSONS JAMES T CPADirectorStock Award(Grant)Jan 1, 202459,937
PAULS DIETRICH JOHNChief Executive OfficerPurchaseJun 22, 202368,591
PILNIK RICHARD DDirectorStock Award(Grant)Jan 1, 2024278,602

Institution ownership

DMAC institution ownership
Holder% heldSharesValueReported
Cooperman, Leon G.3.54%1,511,7398.13MSep 29, 2024
Vanguard Group Inc2.45%1,049,0295.64MSep 29, 2024
First Manhattan Co. LLC1.96%839,0814.51MSep 29, 2024
Paragon Associates & Paragon Associates Ii Joint Venture1.13%482,6142.59MSep 29, 2024
Bleichroeder LP0.89%382,3172.05MSep 29, 2024
Geode Capital Management, LLC0.72%306,9581.65MSep 29, 2024

Fund ownership

DMAC fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.75%747,1984.02MSep 29, 2024
Vanguard Extended Market Index Fund0.59%253,7331.36MSep 29, 2024
Fidelity Extended Market Index Fund0.35%149,057801.18KOct 30, 2024
Jacob Discovery Fd0.27%114,730616.67KOct 30, 2024
iShares Micro Cap ETF0.13%55,116296.25KOct 30, 2024
Fidelity Total Market Index Fund0.11%48,734261.94KOct 30, 2024
Advertisement